Network modeling reveals steps in angiotensin peptide processing

Hypertension

Volumn 61, Issue 3, 2013, Pages 690-700

  Schwacke, John H ^a   Spainhour, John Christian G ^a   Ierardi, Jessalyn L ^a   Chaves, Jose M ^a   Arthur, John M ^a,b   Janech, Michael G ^a,b   Velez, Juan Carlos Q ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

mass spectrometry; proteomics; renin angiotensin system; systems biology

Indexed keywords

ANGIOTENSIN;

ANIMAL CELL; ARTERY THROMBOSIS; BAYES THEOREM; CONFERENCE PAPER; ENZYME ACTIVITY; FOLLOW UP; IN VITRO STUDY; MOLECULAR MODEL; MOUSE; NETWORK LEARNING; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROCESSING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMS BIOLOGY;

ANGIOTENSINS; ANIMALS; BAYES THEOREM; CELL LINE; GLUTAMYL AMINOPEPTIDASE; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MICE; MODELS, BIOLOGICAL; NEPRILYSIN; PEPTIDE FRAGMENTS; PODOCYTES; RENIN-ANGIOTENSIN SYSTEM; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SYSTEMS BIOLOGY;

EID: 84874360564     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00318     Document Type: Conference Paper

References (64)

1. Skrbic R, Igic R. Seven decades of angiotensin (1939-2009). Peptides. 2009;30:1945-1950.
2. Velez JC. The importance of the intrarenal renin-angiotensin system. Nat Clin Pract Nephrol. 2009;5:89-100.
3. Ardaillou R. Angiotensin II receptors. J Am Soc Nephrol. 1999;10(suppl 11):S30-S39.
4. Handa RK, Handa SE, Elgemark MK. Autoradiographic analysis and regulation of angiotensin receptor subtypes AT(4), AT(1), and AT((1-7)) in the kidney. Am J Physiol Renal Physiol. 2001;281:F936-F947.
5. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;100:8258-8263.
6. Gwathmey TM, Alzayadneh EM, Pendergrass KD, Chappell MC. Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol. 2012;302:R518-R530.
7. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345: 851-860.
8. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
9. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446.
10. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
11. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
12. van den Meiracker AH, Man in 't Veld AJ, Admiraal PJ, Ritsema van Eck HJ, Boomsma F, Derkx FH, Schalekamp MA. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response J Hypertens. 1992;10:803-812.
13. Mann JF, Schmieder RE, McQueen M, et al; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, doubleblind, controlled trial. Lancet. 2008;372:547-553.
14. Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol. 1993;33:40-45.
15. Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2010;25:3977-3982.
16. Haulica I, Bild W, Mihaila CN, Ionita T, Boisteanu CP, Neagu B. Biphasic effects of angiotensin (1-7) and its interactions with angiotensin II in rat aorta. J Renin Angiotensin Aldosterone Syst. 2003;4:124-128.
17. Dharmani M, Mustafa MR, Achike FI, Sim MK. Effect of des- aspartateangiotensin I on the actions of angiotensin II in the isolated renal and mesenteric vasculature of hypertensive and STZ-induced diabetic rats. Regul Pept. 2005;129:213-219.
18. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol. 2005;289:H1560-H1566.
19. Kemp BA, Bell JF, Rottkamp DM, Howell NL, Shao W, Navar LG, Padia SH, Carey RM. Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors. Hypertension. 2012;60:387-395.
20. Axelband F, Dias J, Miranda F, Ferrão FM, Reis RI, Costa-Neto CM, Lara LS, Vieyra A. Angiotensin-(3-4) counteracts the angiotensin II inhibitory action on renal Ca2+ATPase through a cAMP/PKA pathway. Regul Pept. 2012;177:27-34.
21. Paula RD, Lima CV, Britto RR, Campagnole-Santos MJ, Khosla MC, Santos RA. Potentiation of the hypotensive effect of bradykinin by angiotensin-( 1-7)-related peptides. Peptides. 1999;20:493-500.
22. Handa RK. Angiotensin-(1-7) can interact with the rat proximal tubule AT(4) receptor system. Am J Physiol. 1999;277(1 pt 2):F75-F83.
23. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86:747-803.
24. Navar LG, Lewis L, Hymel A, Braam B, Mitchell KD. Tubular fluid concentrations and kidney contents of angiotensins I and II in anesthetized rats. J Am Soc Nephrol. 1994;5:1153-1158.
25. Seikaly MG, Arant BS Jr, Seney FD Jr. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest. 1990;86:1352-1357.
26. Gstaiger M, Aebersold R. Applying mass spectrometry-based proteomics to genetics, genomics and network biology. Nat Rev Genet. 2009;10:617-627.
27. Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci USA. 2003;100:6940-6945.
28. Velez JC, Bland AM, Arthur JM, Raymond JR, Janech MG. Characterization of renin-angiotensin system enzyme activities in cultured mouse podocytes. Am J Physiol Renal Physiol. 2007;293:F398-F407.
29. Velez JC, Ierardi JL, Bland AM, Morinelli TA, Arthur JM, Raymond JR, Janech MG. Enzymatic processing of angiotensin peptides by human glomerular endothelial cells. Am J Physiol Renal Physiol. 2012;302:F1583-F1594.
30. Lawhon SD, Khare S, Rossetti CA, Everts RE, Galindo CL, Luciano SA, Figueiredo JF, Nunes JE, Gull T, Davidson GS, Drake KL, Garner HR, Lewin HA, Bäumler AJ, Adams LG. Role of SPI-1 secreted effectors in acute bovine response to Salmonella enterica Serovar Typhimurium: a systems biology analysis approach. PLoS ONE. 2011;6:e26869.
31. Parikh A, Huang E, Dinh C, Zupan B, Kuspa A, Subramanian D, Shaulsky G. New components of the Dictyostelium PKA pathway revealed by Bayesian analysis of expression data. BMC Bioinformatics. 2010;11:163.
32. Sachs K, Perez O, Pe'er D, Lauffenburger DA, Nolan GP. Causal proteinsignaling networks derived from multiparameter single-cell data. Science. 2005;308:523-529.
33. Woolf PJ, Prudhomme W, Daheron L, Daley GQ, Lauffenburger DA. Bayesian analysis of signaling networks governing embryonic stem cell fate decisions. Bioinformatics. 2005;21:741-753.
34. Pe'er D. Bayesian network analysis of signaling networks: a primer. Sci STKE. 2005;2005:pl4.
35. Voit EO. Computational Analysis of Biochemical Systems: a Practical Guide for Biochemists and Molecular Biologists. New York, NY: Cambridge University Press; 2000.
36. Voit EO. Model Identification: a Key Challenge is Computational Systems Biology. Optimization and Systems Biology. Volume 9. Beijing, China: World Publishing Corp; 2008:1-12.
37. Mundel P, Reiser J, Zúñiga Mejía Borja A, Pavenstädt H, Davidson GR, Kriz W, Zeller R. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res. 1997;236:248-258.
38. Velez JC, Ryan KJ, Harbeson CE, Bland AM, Budisavljevic MN, Arthur JM, Fitzgibbon WR, Raymond JR, Janech MG. Angiotensin I is largely converted to angiotensin (1-7) and angiotensin (2-10) by isolated rat glomeruli. Hypertension. 2009;53:790-797.
39. R Development Core Team. A Language and Environment for Statistical Computing [Computer Program]. Viena, Austria: R Foundation for Statistical Computing; 2009.
40. Scutari M. Learning Bayesian Networks with the bnlearn R Package. J Stat Softw. 2010;35:1-22.
41. Grzegorczyk M. An introduction to Gaussian Bayesian networks. Methods Mol Biol. 2010;662:121-147.
42. Hastings WK. Monte Carlo sampling methods using Markov chains and their applications. Biometrika. 1970;57:97-109.
43. Ryan JW, Chung AY, Nearing JA, Valido FA, Shun-Cun C, Berryer P. A radiochemical assay for aminopeptidase N. Anal Biochem. 1993;210:27-33.
44. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383(pt 1):45-51.
45. Iturrioz X, Rozenfeld R, Michaud A, Corvol P, Llorens-Cortes C. Study of asparagine 353 in aminopeptidase A: characterization of a novel motif (GXMEN) implicated in exopeptidase specificity of monozinc aminopeptidases. Biochemistry. 2001;40:14440-14448.
46. Chiu AT, Ryan JW, Stewart JM, Dorer FE. Formation of angiotensin III by angiotensin-converting enzyme. Biochem J. 1976;155:189-192.
47. Bausback HH, Churchill L, Ward PE. Angiotensin metabolism by cerebral microvascular aminopeptidase A. Biochem Pharmacol. 1988;37: 155-160.
48. Goto Y, Hattori A, Ishii Y, Mizutani S, Tsujimoto M. Enzymatic properties of human aminopeptidase A. Regulation of its enzymatic activity by calcium and angiotensin IV. J Biol Chem. 2006;281:23503-23513.
49. Bauvois B, Dauzonne D. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev. 2006;26:88-130.
50. Ahmad S, Ward PE. Role of aminopeptidase activity in the regulation of the pressor activity of circulating angiotensins. J Pharmacol Exp Ther. 1990;252:643-650.
51. Yatabe J, Yoneda M, Yatabe MS, Watanabe T, Felder RA, Jose PA, Sanada H. Angiotensin III stimulates aldosterone secretion from adrenal gland partially via angiotensin II type 2 receptor but not angiotensin II type 1 receptor. Endocrinology. 2011;152:1582-1588.
52. Plovsing RR, Wamberg C, Sandgaard NC, Simonsen JA, Holstein-Rathlou NH, Hoilund-Carlsen PF, Bie P. Effects of truncated angiotensins in humans after double blockade of the renin system. Am J Physiol Regul Integr Comp Physiol. 2003;285:R981-R991.
53. Handa RK. Biphasic actions of angiotensin IV on renal blood flow in the rat. Regul Pept. 2006;136:23-29.
54. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension. 1991;18:763-773.
55. Nadarajah R, Milagres R, Dilauro M, Gutsol A, Xiao F, Zimpelmann J, Kennedy C, Wysocki J, Batlle D, Burns KD. Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int. 2012;82:292-303.
56. Kaneshiro Y, Ichihara A, Sakoda M, Takemitsu T, Nabi AH, Uddin MN, Nakagawa T, Nishiyama A, Suzuki F, Inagami T, Itoh H. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol. 2007;18:1789-1795.
57. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008;57:3297-3306.
58. Cristovam PC, Arnoni CP, de Andrade MC, Casarini DE, Pereira LG, Schor N, Boim MA. ACE-dependent and chymase-dependent angiotensin II generation in normal and glucose-stimulated human mesangial cells. Exp Biol Med (Maywood). 2008;233:1035-1043.
59. Ramírez M, Prieto I, Martinez JM, Vargas F, Alba F. Renal aminopeptidase activities in animal models of hypertension. Regul Pept. 1997;72: 155-159.
60. Oliveira V, Ferro ES, Gomes MD, Oshiro ME, Almeida PC, Juliano MA, Juliano L. Characterization of thiol-, aspartyl-, and thiol-metallopeptidase activities in Madin-Darby canine kidney cells. J Cell Biochem. 2000;76:478-488.
61. Chappell MC, Gomez MN, Pirro NT, Ferrario CM. Release of angiotensin-( 1-7) from the rat hindlimb: influence of angiotensin-converting enzyme inhibition. Hypertension. 2000;35(1 pt 2):348-352.
62. Park S, Bivona BJ, Kobori H, Seth DM, Chappell MC, Lazartigues E, Harrison-Bernard LM. Major role for ACE-independent intrarenal ANG II formation in type II diabetes. Am J Physiol Renal Physiol. 2010;298: F37-F48.
63. Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erdös EG. N-domain-specific substrate and C-domain inhibitors of angiotensinconverting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension. 1998;31:912-917.
64. Jankowski V, Vanholder R, van der Giet M, et al. Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol. 2007;27:297-302.